PL2121677T3 - Nowe pochodne chromen-2-onu i ich zastosowanie jako inhibitorów wychwytu zwrotnego neurotransmiteru monoaminowego - Google Patents

Nowe pochodne chromen-2-onu i ich zastosowanie jako inhibitorów wychwytu zwrotnego neurotransmiteru monoaminowego

Info

Publication number
PL2121677T3
PL2121677T3 PL07857757T PL07857757T PL2121677T3 PL 2121677 T3 PL2121677 T3 PL 2121677T3 PL 07857757 T PL07857757 T PL 07857757T PL 07857757 T PL07857757 T PL 07857757T PL 2121677 T3 PL2121677 T3 PL 2121677T3
Authority
PL
Poland
Prior art keywords
derivatives
uptake inhibitors
monoamine neurotransmitter
novel chromen
chromen
Prior art date
Application number
PL07857757T
Other languages
English (en)
Polish (pl)
Inventor
Dan Peters
John Paul Redrobe
Gunnar M Olsen
ELSEBET øSTERGAARD NIELSEN
Original Assignee
Neurosearch As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurosearch As filed Critical Neurosearch As
Publication of PL2121677T3 publication Critical patent/PL2121677T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL07857757T 2006-12-20 2007-12-18 Nowe pochodne chromen-2-onu i ich zastosowanie jako inhibitorów wychwytu zwrotnego neurotransmiteru monoaminowego PL2121677T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US87580606P 2006-12-20 2006-12-20
DKPA200601678 2006-12-20
PCT/EP2007/064130 WO2008074797A1 (en) 2006-12-20 2007-12-18 Novel chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
EP07857757A EP2121677B1 (en) 2006-12-20 2007-12-18 Novel chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors

Publications (1)

Publication Number Publication Date
PL2121677T3 true PL2121677T3 (pl) 2011-04-29

Family

ID=39284195

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07857757T PL2121677T3 (pl) 2006-12-20 2007-12-18 Nowe pochodne chromen-2-onu i ich zastosowanie jako inhibitorów wychwytu zwrotnego neurotransmiteru monoaminowego

Country Status (10)

Country Link
US (1) US8263617B2 (cg-RX-API-DMAC7.html)
EP (1) EP2121677B1 (cg-RX-API-DMAC7.html)
JP (1) JP2010513391A (cg-RX-API-DMAC7.html)
AU (1) AU2007336290A1 (cg-RX-API-DMAC7.html)
CA (1) CA2673315A1 (cg-RX-API-DMAC7.html)
IL (1) IL198762A0 (cg-RX-API-DMAC7.html)
MX (1) MX2009006213A (cg-RX-API-DMAC7.html)
NO (1) NO20092719L (cg-RX-API-DMAC7.html)
PL (1) PL2121677T3 (cg-RX-API-DMAC7.html)
WO (1) WO2008074797A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200800980A (en) 2006-02-17 2008-01-01 Neurosearch As Novel compounds
TW200904815A (en) 2007-05-09 2009-02-01 Neurosearch As Novel compounds
US8697721B2 (en) 2009-05-15 2014-04-15 Aniona Aps Chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
WO2011092061A1 (en) 2010-01-29 2011-08-04 Neurosearch A/S Chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2157462T3 (es) 1995-10-13 2001-08-16 Aventis Cropscience Uk Ltd Fungicidas heterociclicos.
US5916914A (en) 1997-08-08 1999-06-29 Warner-Lambert Company Compounds and method of treating psychosis and schizophrenia
JP2002518331A (ja) 1998-06-19 2002-06-25 イーライ・リリー・アンド・カンパニー セロトニン再取り込みの阻害
WO2003106452A2 (en) * 2002-06-12 2003-12-24 Millennium Pharmaceuticals, Inc. Antagonists of melanin concentrating hormone receptor
EP2284170A1 (en) * 2004-09-30 2011-02-16 NeuroSearch AS Novel chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
MX2007002384A (es) * 2004-09-30 2007-05-11 Neurosearch As Nuevos derivados de cromen-2-ona y su uso como inhibidores de la reabsorcion del neurotransmisor de monoamina.
US7781456B2 (en) 2004-12-17 2010-08-24 Neurosearch A/S Enantiomers of 3-heteroaryl-8H-8-azabicyclo(3.2.1)oct-2-ene and their use as monoamine neurotransmitter re-uptake inhibitors
TW200800980A (en) 2006-02-17 2008-01-01 Neurosearch As Novel compounds
EP2121678B1 (en) * 2006-12-20 2010-11-03 NeuroSearch A/S Novel chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
CA2734797A1 (en) * 2008-08-21 2010-02-25 Neurosearch A/S Treatment of anxiety disorders

Also Published As

Publication number Publication date
JP2010513391A (ja) 2010-04-30
EP2121677A1 (en) 2009-11-25
US20100029711A1 (en) 2010-02-04
MX2009006213A (es) 2010-06-30
WO2008074797A1 (en) 2008-06-26
CA2673315A1 (en) 2008-06-26
EP2121677B1 (en) 2010-11-03
IL198762A0 (en) 2010-02-17
NO20092719L (no) 2009-07-17
AU2007336290A1 (en) 2008-06-26
US8263617B2 (en) 2012-09-11

Similar Documents

Publication Publication Date Title
HRP20181622T1 (hr) Imidazotriazini i imidazopirimidini kao inhibitori kinaze
GB0700919D0 (en) Degradable compositions, apparatus comprising same, and methods of use
IL192613A0 (en) Cycloalkylamines as monoamine reuptake inhibitors
IL195619A0 (en) Compositions and methods for joininig non-conjoined iumens
PL2040728T3 (pl) FKBP-L i jego zastosowanie jako inhibitora angiogenezy
PT2094263E (pt) Derivados da 2-adamantil-butiramida como inibidores seletivos da 11-beta-hsd1
IL192603A0 (en) Thieno-pyridine derivatives as mek inhibitors
IL210843A0 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
PL2078001T3 (pl) Pochodne diazepano-acetamidowe jako selektywne inhibitory 11-hsd1
EP2239261A4 (en) PYRROLOPYRIMIDINE DERIVATIVE FOR USE AS A PI3K INHIBITOR AND USE THEREOF
EP2101731A4 (en) PROCESSES AND COMPOSITIONS WITH END OXIFES
ZA200902255B (en) Synthesis, methods of using, and compositions of cycloalkylmethylamines
IL196000A0 (en) 2-arylindole derivatives as npges-i inhibitors
GB0601143D0 (en) Uses, methods and compositions
IL209406A0 (en) Novel tetramethyl substituted piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
IL192485A0 (en) Novel chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
IL195014A0 (en) Benzazepine derivatives as monoamine reuptake inhibitors
IL187575A0 (en) Benzofuranyl derivatives as 5-ht6-receptor inhibitors
ZA200806434B (en) Calcium-enrichment compositions and methods for production thereof
EP2029132A4 (en) ANTIHISTAMINE COMPOSITIONS AND THEIR USE
IL198762A0 (en) Novel chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
GB0622399D0 (en) Novel compositions and uses thereof
GB0617171D0 (en) Novel compositions and methods
ZA200903278B (en) Novel chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
IL180777A0 (en) Novel chromen-2- one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors